Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) - guidance (TA382)
- National Institute for Health and Care Excellence - NICE
- Publication date:
- 27 January 2016
NICE was unable to make recommendations on eltrombopag (Revolade) for severe aplastic anaemia refractory to immunosuppressive therapy because no evidence submission was received from Novartis, but will review this decision if the company decides to make a submission.